Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ASCO 2022
At #ASH25, we spoke with the lovely @AbdulhaqHaifaa of @UCSF, who discussed a subgroup analysis from the STARGLO trial evaluating the efficacy of glofitamab plus GemOx versus R-GemOx in transplant-ineligible patients with R/R #DLBCL.
Watch now:
🎥
#LYMsm… https://twitter.com/i/web/status/2010275551328526721
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO
Haifaa Abdulhaq, MD, University of California San Francisco, San Francisco, CA, discusses a subgroup analysis from the...
ow.ly
It was a pleasure to catch up with @LesokhinMD of @MSKCancerCenter at #ASH25 to hear about a post-hoc analysis of the MagnetisMM-3 trial evaluating the feasibility & safety of prolonged elranatamab interruption in R/R #myeloma.
Watch here: 👉
#MMSM… https://twitter.com/i/web/status/2010049111274189147
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
In this video, Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the results of ...
ow.ly
🎥 Adlette Inati of @lebamericanuni presents findings from the first cohort of the ongoing Phase I/II HIBISCUS Kids study, which investigates the PK activator etavopivat in children & adolescents with #SickleCellDisease:
👉 👈
#ASH25 #Hematology #CTSM… https://twitter.com/i/web/status/2009905608930017597
Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
Adlette Inati, MD, Lebanese American University, Blat, Lebanon, discusses safety and efficacy findings from the first ...
ow.ly
Watch our interview from #ASH25 with Lynette Chee of @PeterMacCC to hear updated results from an ongoing Phase II trial of elritercept in patients with transfusion-dependent LR-MDS.🩸
Click here: 👉
#MDSsm #CTSM #TrialUpdate #HemOnc
Updated results from a Phase II trial of elritercept in LR-MDS
Lynette Chee, MBBS, PhD, The Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Melbourne, Australia, shares updated ...
ow.ly
Our latest podcast dives into key multiple myeloma updates from #ASH25 🩸
From redefining functional high-risk disease to CAR-T and T-cell engagers.
🎧 Listen here:
Featuring Luciano Costa (@End_myeloma), Nisha Joseph (@nishjo76), Shambavi Richard,… https://twitter.com/i/web/status/2009671857071411501
Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T,...
This podcast features key updates in multiple myeloma from ASH 2025. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham,...
ow.ly
ASCO 2022
At #ASH25, we spoke with the lovely @AbdulhaqHaifaa of @UCSF, who discussed a subgroup analysis from the STARGLO trial evaluating the efficacy of glofitamab plus GemOx versus R-GemOx in transplant-ineligible patients with R/R #DLBCL.
Watch now:
🎥
#LYMsm… https://twitter.com/i/web/status/2010275551328526721
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO
Haifaa Abdulhaq, MD, University of California San Francisco, San Francisco, CA, discusses a subgroup analysis from the...
ow.ly
It was a pleasure to catch up with @LesokhinMD of @MSKCancerCenter at #ASH25 to hear about a post-hoc analysis of the MagnetisMM-3 trial evaluating the feasibility & safety of prolonged elranatamab interruption in R/R #myeloma.
Watch here: 👉
#MMSM… https://twitter.com/i/web/status/2010049111274189147
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
In this video, Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the results of ...
ow.ly
🎥 Adlette Inati of @lebamericanuni presents findings from the first cohort of the ongoing Phase I/II HIBISCUS Kids study, which investigates the PK activator etavopivat in children & adolescents with #SickleCellDisease:
👉 👈
#ASH25 #Hematology #CTSM… https://twitter.com/i/web/status/2009905608930017597
Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
Adlette Inati, MD, Lebanese American University, Blat, Lebanon, discusses safety and efficacy findings from the first ...
ow.ly
Watch our interview from #ASH25 with Lynette Chee of @PeterMacCC to hear updated results from an ongoing Phase II trial of elritercept in patients with transfusion-dependent LR-MDS.🩸
Click here: 👉
#MDSsm #CTSM #TrialUpdate #HemOnc
Updated results from a Phase II trial of elritercept in LR-MDS
Lynette Chee, MBBS, PhD, The Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Melbourne, Australia, shares updated ...
ow.ly
Our latest podcast dives into key multiple myeloma updates from #ASH25 🩸
From redefining functional high-risk disease to CAR-T and T-cell engagers.
🎧 Listen here:
Featuring Luciano Costa (@End_myeloma), Nisha Joseph (@nishjo76), Shambavi Richard,… https://twitter.com/i/web/status/2009671857071411501
Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T,...
This podcast features key updates in multiple myeloma from ASH 2025. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham,...
ow.ly
